non small cell lung cancer
Conditions
Interventions
A:Standard radiotherapy
B:Stratified radiotherapy
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. More than 18 years old; 2. ECOG score 0-2 points; 3. Histology or cytology confirmed as non-small cell lung cancer; 4. Various examinations confirmed to be inoperable stage II to III locally advanced non-small cell lung cancer, and the primary lesion was greater than 3 cm; 5. Life expectancy > 6 months; 6. Women of childbearing age must undergo a pregnancy test (serum or urine) within 7 days prior to enrollment and the results are negative and willing to use appropriate methods of contraception during the trial and within 8 weeks of the last administration of the test drug. For men, consent must be given to the use of appropriate methods of contraception or surgical sterilization during the trial period and within 8 weeks after the last administration of the test drug; 7. Ability to follow research and follow-up procedures; 8. Subjects understand and voluntarily sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Radiotherapy is not possible due to severe comorbidities; 2. Radiotherapy has been performed on the site in need of treatment; 3. There is a distant metastasis, there is a malignant chest or pericardial effusion; 5. No amount can be added to the tumor; 7. Any unstable systemic disease (including active infection, poorly controlled hypertension, unstable angina, congestive heart failure, liver, kidney or metabolic disease); 8. Patients who do not receive oral administration, require intravenous high-energy nutrition, have previously had an effect of absorption, or have active gastrointestinal ulcers; 9. Pregnant or lactating women; 10. The patient's main organ function is abnormal, that is, the following criteria are met: The granulocyte count is less than 1.5*109/L, the platelet count is less than 100*109/L; the serum bilirubin is 1.5 times larger than the upper limit of normal, AST and ALT are more than twice the upper limit of normal, and if there is liver metastasis, higher than 5 times of normal. Upper limit; serum creatinine is greater than 1.5 times the upper limit of normal, or creatinine clearance is less than 50 ml/min.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival;disease control rate;objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;the acute toxicity;the late toxicity; | — |
Countries
China
Contacts
Public ContactJiancheng Li
Fujian Cancer Hospital
Outcome results
None listed